# Gilead Sciences, Inc. – Consensus ‘buy’ rating and 8.8% Upside Potential

- Link: https://www.directorstalkinterviews.com/gilead-sciences-inc.consensus-buy-rating-and-8.8-upside-potential/4121131805
- Published: 2023-11-01T14:25:56+00:00
- Author: Charlotte Edwards

**Gilead Sciences, Inc.** with ticker code (GILD) have now 24 market analysts covering
the stock. The analyst consensus now points to a rating of ‘buy’. The target price
High/Low ranges between $109.40 and $66.96 suggesting an average Analsyt target 
price of $85.47. Given that the stocks previous close was at $78.54 this now indicates
there is a potential upside of 8.8%. The 50 day MA is $76.50 and the 200 day MA 
is $79.22. The company has a market cap of 98.36B. The stock price is currently 
at: $78.94 USD

 The potential market cap would be $107,038,859,746 based on the market consensus.

The company is not paying dividends at this time.

Other points of data to note are a P/E ratio of 18.15, revenue per share of $21.87
and a 9.77% return on assets.

Gilead Sciences, Inc. is a biopharmaceutical company. The Company is engaged in 
advancing medicines to prevent and treat life-threatening diseases, including human
immunodeficiency virus (HIV), viral hepatitis and cancer. The Company offers products
in HIV, Onocolgy, Liver Disease, Vekulaery, and Other. Under HIV, it offers Biktarvy,
Complera/Eviplera, Genvoya, Odefsey, Stribild, and Truvada. Its Veklury (remdesivir)
is a nucleotide analog RNA polymerase inhibitor indicated for the treatment of coronavirus
disease 2019 (COVID-19). Under oncology it offers cell therapy containing Tecartus
and Yescarta. Under this Liver Disease consists of Chronic hepatitis C virus (HCV)(
Ledipasvir/Sofosbuvir and Sofosbuvir/Velpatasvir) and Chronic hepatitis B virus (
HBV) / hepatitis delta virus (HDV) (Vemlidy and Viread). The Company’s other products
include AmBisome and Letairis. It also operates a portfolio of small molecule inhibitors
targeting PARP1 for oncology and MK2 for inflammatory diseases.

Share on: